Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India
· Delayed Price · Currency is INR 1,590.20
+5.40 (0.34%)
Jun 6, 2025, 3:30 PM IST
Glenmark Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Net Income | 10,471 | -15,017 | 2,972 | 9,417 | 9,700 | Upgrade
|
| Depreciation & Amortization | 4,860 | 4,792 | 3,810 | 1,613 | 3,162 | Upgrade
|
| Other Amortization | - | 1,517 | 2,303 | 3,254 | 1,273 | Upgrade
|
| Loss (Gain) From Sale of Assets | 25.42 | -8.26 | -57.25 | 64.64 | -3.54 | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.27 | -7,450 | -0.26 | -149.81 | -0.34 | Upgrade
|
| Stock-Based Compensation | -91.67 | 49.62 | 67.74 | 79.16 | 79.37 | Upgrade
|
| Provision & Write-off of Bad Debts | 30.97 | 176.5 | 118.72 | 298.74 | 113.69 | Upgrade
|
| Other Operating Activities | 1,715 | 15,928 | 1,499 | 2,122 | 845.41 | Upgrade
|
| Change in Accounts Receivable | -14,203 | 9,695 | -8,487 | -5,493 | -1,179 | Upgrade
|
| Change in Inventory | -4,508 | -5,139 | -3,752 | -2,034 | -1,338 | Upgrade
|
| Change in Accounts Payable | -8,138 | -7,344 | 1,662 | 847.57 | 1,605 | Upgrade
|
| Change in Other Net Operating Assets | 1,562 | -5,182 | -167.73 | 1,067 | -2,946 | Upgrade
|
| Operating Cash Flow | -8,276 | -2,654 | 6,254 | 11,087 | 11,312 | Upgrade
|
| Operating Cash Flow Growth | - | - | -43.59% | -1.99% | -18.76% | Upgrade
|
| Capital Expenditures | -7,496 | -8,984 | -6,078 | -7,901 | -7,748 | Upgrade
|
| Sale of Property, Plant & Equipment | 24.2 | 20.8 | 572.29 | 15.8 | 994.33 | Upgrade
|
| Divestitures | - | 54,496 | - | - | - | Upgrade
|
| Investment in Securities | 7,333 | - | -10.08 | -100.18 | - | Upgrade
|
| Other Investing Activities | 159.63 | 75.82 | 230.51 | 4,653 | 0.89 | Upgrade
|
| Investing Cash Flow | 20.94 | 45,609 | -5,285 | -3,333 | -6,752 | Upgrade
|
| Short-Term Debt Issued | 8,339 | 4,811 | - | - | 855.71 | Upgrade
|
| Long-Term Debt Issued | 5,072 | - | 11,632 | 21,301 | 16,443 | Upgrade
|
| Total Debt Issued | 13,412 | 4,811 | 11,632 | 21,301 | 17,299 | Upgrade
|
| Short-Term Debt Repaid | - | - | -200 | -1,417 | - | Upgrade
|
| Long-Term Debt Repaid | -2,629 | -37,539 | -6,198 | -31,201 | -18,076 | Upgrade
|
| Total Debt Repaid | -2,629 | -37,539 | -6,398 | -32,618 | -18,076 | Upgrade
|
| Net Debt Issued (Repaid) | 10,783 | -32,728 | 5,234 | -11,317 | -777.1 | Upgrade
|
| Issuance of Common Stock | - | 12 | - | - | - | Upgrade
|
| Common Dividends Paid | -704.42 | -704.52 | -703.86 | -926.95 | -704.47 | Upgrade
|
| Other Financing Activities | -2,208 | -5,641 | -5,305 | 7,040 | -2,936 | Upgrade
|
| Financing Cash Flow | 7,870 | -39,061 | -774.56 | -5,205 | -4,418 | Upgrade
|
| Foreign Exchange Rate Adjustments | 558.93 | 176.79 | 123.87 | 175.5 | 136.22 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | -1,918 | 6.68 | - | - | Upgrade
|
| Net Cash Flow | 174.37 | 2,152 | 325 | 2,724 | 278.2 | Upgrade
|
| Free Cash Flow | -15,772 | -11,638 | 176.29 | 3,185 | 3,565 | Upgrade
|
| Free Cash Flow Growth | - | - | -94.47% | -10.64% | -22.68% | Upgrade
|
| Free Cash Flow Margin | -11.74% | -9.20% | 0.15% | 2.59% | 3.26% | Upgrade
|
| Free Cash Flow Per Share | -55.88 | -41.24 | 0.63 | 11.29 | 12.63 | Upgrade
|
| Cash Interest Paid | 1,908 | 5,168 | 3,115 | 2,505 | 2,936 | Upgrade
|
| Cash Income Tax Paid | 6,801 | 10,475 | 6,405 | 5,584 | 5,102 | Upgrade
|
| Levered Free Cash Flow | -15,375 | 43,246 | -11,604 | 1,853 | 1,154 | Upgrade
|
| Unlevered Free Cash Flow | -14,081 | 46,471 | -9,423 | 3,716 | 3,361 | Upgrade
|
| Change in Net Working Capital | 23,723 | -40,061 | 16,639 | 4,830 | 4,132 | Upgrade
|
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.